
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd is a strong contender in the race to develop an effective treatment for COVID-19, with promising results in clinical trials and FDA support for their lead product PEMGARDA. The company's focus on monoclonal antibody therapies for viral infectious diseases sets them apart in an increasingly competitive market, but there are potential challenges and risks that should be carefully considered. Overall, Invivyd's dedication to research and development and potential for success make it a promising investment opportunity in the biopharmaceutical industry.
Bears say
Invivyd is facing intense competition in the biopharmaceutical industry, particularly in the field of monoclonal antibodies for COVID-19. While their lead product, PEMGARDA, received FDA emergency use authorization, there are concerns about the effectiveness of the product in the face of new variants like Omicron. Additionally, their pipeline is still in early stages of development, leaving them vulnerable to setbacks and delays.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares